Statistics from Altmetric.com
A 48-year-old Japanese woman with non-small cell lung adenocarcinoma (cT3N2M1b) received nivolumab (an immune checkpoint inhibitor) at a dosage of 3 mg/kg every 2 weeks. Treatment with nivolumab was effective. The primary tumour as well as metastases to the lymph nodes and spine almost completely disappeared, as shown on positron emission tomography-CT before treatment (figure 1A) and 4 months after treatment (figure 1B). However, she developed sustained pain and swelling in the shoulders and knees bilaterally after only one infusion of nivolumab, and active inflammation was detected in the shoulder joints bilaterally (figure 1B). She had no personal and family histories of autoimmune disease. Serum C-reactive protein level was 2.1 mg/L. Serum matrix metalloproteinase-3 was elevated at 209 ng/mL (normal <60). Antinuclear antibody, rheumatoid factor and anti-cyclic citrullinated peptide antibody were negative. Ultrasonography confirmed shoulder tenosynovitis and bursitis (figure 2). The arthritis responded well to low-dose prednisone, and she could continue to receive nivolumab. General physicians are encountering an increasing number of immune-related adverse events with increased use of immune checkpoint inhibitors.1 Our case provides instructive images demonstrating both the efficacy of immune checkpoint inhibitors and the associated immune-related adverse events.
An increasing number of immune-related adverse events have been described with the increased use of nivolumab, an immune checkpoint inhibitor.
This case provides instructive images showing both the efficacy of the immune checkpoint inhibitors and the associated immune-related adverse events.
Contributors SK and YM involved in conception or design of the work. SK and KK are responsible for acquisition of data. SK, KK, TM and YM are responsible for analysis and interpretation of data. SK, TM and YM drafted or revised the manuscript.
Competing interests SK, TM and YM received scholarship donations from AbbVie, Actelion, Astellas, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Japan Blood Products Organization, Mitsubishi-Tanabe, MSD, Pfizer, Shionogi, Takeda, Teijin and UCB. KK received scholarship donations from Astellas, Boehringer lngelheim, Chugai, MSD, Ono and Taiho.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.